Cytyc gains FDA OK for ThinPrep vial testing:
This article was originally published in Clinica
Executive Summary
The US FDA has approved testing for Chlamydia trachomatis (CT) and Neisseria gonorrhoea (NG) directly from Cytyc's ThinPrep Pap test collection vial using Roche Diagnostics' COBAS AMPLICOR automated system. The approval allows physicians to check for chlamydia and gonorrhoea infections, plus human papilloma virus infection and cervical lesions using a single ThinPrep Pap test specimen, says Boxborough, Massachusetts-based Cytyc. Chlamydia is the most common bacterial sexually transmitted disease in the US and is asymptomatic in around 75% of cases.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.